行情

CANF

CANF

CAN FITE BIOPHAR
AMEX

实时行情|Nasdaq Last Sale

2.420
-0.060
-2.42%
已收盘, 19:14 11/12 EST
开盘
2.540
昨收
2.480
最高
2.540
最低
2.380
成交量
4.94万
成交额
--
52周最高
25.95
52周最低
1.900
市值
804.41万
市盈率(TTM)
-0.0319
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CANF 新闻

  • Can-Fite Obtains Patent For Treatment Of Osteoarthritis In Mammals
  • Benzinga.1天前
  • Can-Fite Obtains Patent For Treatment Of Osteoarthritis In Mammals
  • Benzinga.1天前
  • Can-Fite Granted US Patent for Piclidenoson in the Treatment of Osteoarthritis
  • Benzinga.1天前
  • Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market
  • Business Wire.1天前

更多

所属板块

生物技术和医学研究
+0.45%
制药与医学研究
+0.31%

热门股票

名称
价格
涨跌幅

CANF 简况

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.
展开

Webull提供Can Fite Biopharma Ltd的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。